<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment-related toxicity in testicular germ cell tumors</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment-related toxicity in testicular germ cell tumors</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment-related toxicity in testicular germ cell tumors</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">M Dror Michaelson, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Begoña P Valderrama, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Timothy D Gilligan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 10, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Testicular cancers, 95 percent of which are germ cell tumors, are among the most curable solid neoplasms. Testicular germ cell tumors (GCTs) are more sensitive to systemic chemotherapy than any other adult solid tumor. Conventional cisplatin-based regimens can cure up to 80 percent of patients with disseminated GCTs, including those with widespread visceral metastases [<a href="#rid1">1</a>]. An additional group of patients who relapse or have refractory disease can also be cured with further systemic therapy. Since most males with testicular GCTs are long-term survivors, minimizing treatment-related toxicity is a primary concern.</p><p>The adverse effects of conventional doses of commonly used chemotherapeutic agents in testicular GCTs are discussed in this topic. The management of long-term survivors and the late effects of radiation therapy are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors"</a>.)</p><p class="headingAnchor" id="H970172098"><span class="h1">IMPACT OF CISPLATIN-BASED CHEMOTHERAPY</span><span class="headingEndMark"> — </span>The long-term disease-free survival for testicular germ cell tumor patients is approximately 95 percent, and these results rely heavily on the use of cisplatin-based chemotherapy regimens for patients with advanced disease. However, cisplatin-based chemotherapy is associated with clinically important long-term toxicities.</p><p>An extensive study of the impact of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> chemotherapy on testicular cancer survivors comes from the multi-institutional Platinum Study Group, which assessed a wide range of adverse health outcomes in 952 males [<a href="#rid2">2</a>]. All study participants had been treated with cisplatin-based chemotherapy (predominantly <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and cisplatin [BEP] for three or four cycles or etoposide plus cisplatin [EP] for four cycles). None had received radiation therapy or salvage chemotherapy, and all were disease-free at the time of assessment. The median age was 37 years, and the median time following chemotherapy was 4.3 years. Patients were assessed with a brief physical examination, audiometric testing, and a detailed questionnaire regarding selected health outcomes.</p><p>No adverse health outcomes were detected or reported in 20 percent, one or two in 42 percent, three or four in 25 percent, and five or more in 13 percent of cases. The most commonly reported adverse health outcomes were tinnitus, hearing impairment, and peripheral neuropathy in 37, 32, and 27 percent of cases, respectively. A combination of peripheral neuropathy and ototoxicity was observed in 16 percent. The patterns of toxicity were similar with the BEP and EP regimens, except that Reynaud phenomenon and obesity were more common with BEP (12 versus 21 and 26 versus 33 percent, respectively), while peripheral neuropathy was more common with EP (29 versus 21 percent). </p><p>Of note, ototoxicity was significantly more frequent when assessed with formal audiometric testing [<a href="#rid3">3</a>]. (See <a class="local">'Ototoxicity'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">HEMATOLOGIC</span><span class="headingEndMark"> — </span>For males with good-risk testicular germ cell tumors (GCTs), standard dose chemotherapy (three cycles of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> [BEP  (<a class="graphic graphic_table graphicRef65516" href="/z/d/graphic/65516.html" rel="external">table 1</a>)], or four courses of etoposide and cisplatin [EP]) is generally well tolerated. (See  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors", section on 'Good risk'</a>.)</p><p>Following each course of chemotherapy, the hematologic nadir will generally occur in week 2 or 3 and may extend into the beginning of the subsequent cycle. A low white blood cell count at the beginning of a subsequent course of chemotherapy does not mandate dose reduction or treatment delay unless the previous cycle was a complicated and significant clinical event, such as febrile neutropenia.</p><p>The concept that full doses should be administered at the scheduled time, regardless of the white blood cell count, is important; the curative potential of systemic chemotherapy may otherwise be compromised. While we do not use prophylactic hematopoietic growth factors (eg, granulocyte colony stimulating factors [G-CSF]) at the start of treatment, we recommend initiation of G-CSF in patients who develop low blood cell counts (on day 1 of the subsequent cycle) and those who had a complicated neutropenic event (eg, febrile neutropenia).</p><p>In patients treated with first-line chemotherapy who relapse and are subsequently treated with <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">ifosfamide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (TIP)  (<a class="graphic graphic_table graphicRef134377" href="/z/d/graphic/134377.html" rel="external">table 2</a>), primary prophylaxis with G-CSF is indicated, given the high risk of neutropenic fever with this regimen. (See  <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">"Diagnosis and treatment of relapsed and refractory testicular germ cell tumors", section on 'Treatment after three or four cycles of cisplatin-based chemotherapy'</a> and  <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">"Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">PULMONARY</span></p><p class="headingAnchor" id="H4"><span class="h2">Bleomycin toxicity</span><span class="headingEndMark"> — </span>The most serious pulmonary toxicities associated with chemotherapy for testicular germ cell tumors (GCTs) are the pneumonitis and pulmonary fibrosis attributed to <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>. The incidence of bleomycin lung injury is cumulative, increasing significantly above 450 units. Predictive factors for the development of pulmonary toxicity include advanced age, prior or concurrent thoracic radiation therapy (RT), and renal dysfunction (particularly due to concomitant <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>). (See  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p>Approximately one-half of all treatment-related deaths in males treated with chemotherapy for testicular cancer are due to bleomycin-induced pulmonary fibrosis, which is fatal in 50 percent of patients [<a href="#rid1">1</a>]. The incidence of fatal <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> lung toxicity with four cycles of bleomycin, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) is 1 to 2 percent, but is less than 1 percent when BEP is limited to three cycles [<a href="#rid1">1,4-8</a>]. This low risk may be due to the fact that bleomycin is generally discontinued if patients show early signs of pneumonitis, although this is unproven.</p><p>Signs and symptoms suggestive of early lung toxicity include a non-productive cough, exertional dyspnea, and bibasilar crackles. Pulmonary nodules may be seen on chest imaging studies, although findings do not correlate with long-term damage [<a href="#rid9">9</a>]. Nevertheless, it is standard practice to eliminate further <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> if radiographic changes are observed during treatment.</p><p>Although pulmonary function tests (PFTs) are neither sensitive nor specific for <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> lung toxicity, the best diagnostic tool for early detection is measurement of the diffusing capacity for carbon monoxide (DLCO) [<a href="#rid10">10</a>]. A decline in DLCO may be the earliest sign of lung injury. At most centers, baseline PFTs are established prior to chemotherapy and are then repeated at the start of each new cycle. Several authors recommend that bleomycin be discontinued if the DLCO falls by 40 percent or if it falls to less than 60 percent of an individual's baseline value [<a href="#rid11">11-13</a>]. (See  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p>Despite the potential for fatal pulmonary toxicity from <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, three or four courses of BEP or <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, and bleomycin (PVB) chemotherapy in males with testicular cancer does not appear to lead to long-term impairment of pulmonary function. The most extensive data come from a series of 565 patients who were evaluated with PFTs before or after treatment [<a href="#rid14">14</a>]. Although DLCO decreased during treatment, it rebounded to normal in most patients with long-term follow-up. Patients who had had pulmonary surgery or a pulmonary embolus, and those in the International Germ Cell Consensus Classification (IGCCC) poor prognostic group were at increased risk for late pulmonary impairment.</p><p class="headingAnchor" id="H5"><span class="h2">Late chemotherapy toxicity</span><span class="headingEndMark"> — </span>High cumulative doses of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> chemotherapy may also be associated with late impairment of pulmonary function and restrictive lung disease.</p><p>Pulmonary function and symptoms were analyzed with spirometry and a symptom questionnaire in a cohort of 1049 five-year survivors who had been treated in Norway between 1980 and 1994 [<a href="#rid15">15</a>]. Patients were divided into five treatment cohorts: orchiectomy only, RT, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> cumulative dose ≤850 mg, cisplatin cumulative dose &gt;850 mg, and cisplatin (any dose) with pulmonary surgery.</p><p>At a median observation time of 11 years, the incidence of restrictive physiology was significantly increased in patients treated with high doses of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> or with cisplatin plus pulmonary surgery (18 and 17 percent, respectively, versus 7 percent in patients treated with orchiectomy alone). The observed changes in restrictive physiology were more closely correlated with cumulative cisplatin dose than <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> dose, suggesting that cisplatin may also have long-term important effects on pulmonary function.</p><p>Clinicians caring for long-term survivors of testicular cancer should be aware of the potential for chemotherapy to adversely affect pulmonary function in some patients.</p><p class="headingAnchor" id="H6"><span class="h2">Prevention of late pulmonary toxicity</span><span class="headingEndMark"> — </span>Acute respiratory failure from adult respiratory distress syndrome has been reported following general anesthesia in patients previously treated with <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> [<a href="#rid16">16,17</a>]. It was suspected that exposure to high concentrations of oxygen could provoke latent pulmonary toxicity by increasing free radical formation in the lungs [<a href="#rid4">4,16</a>]. However, a review of 77 patients undergoing major surgery following bleomycin-containing chemotherapy failed to demonstrate a correlation between perioperative oxygen restriction and either postoperative pulmonary morbidity or survival [<a href="#rid18">18</a>]. These authors suggested that careful fluid management during surgery was more important than oxygen restriction.</p><p>Nevertheless, patients treated with <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> at any time in the past should not be exposed to high concentrations of inspired oxygen (either in the operating room or elsewhere) unless medically necessary to treat or prevent hypoxemia. When undergoing surgery, fluid balance must be carefully monitored, and intravenous fluids and blood products administered judiciously. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury", section on 'Supplemental oxygen and future perioperative management'</a>.)</p><p class="headingAnchor" id="H7"><span class="h1">RENAL</span><span class="headingEndMark"> — </span>The general aspects of renal toxicity associated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> are discussed in detail elsewhere. Here we will focus on the available data in males receiving cisplatin-based regimens for testicular cancer. (See  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Renal insufficiency</span><span class="headingEndMark"> — </span>Despite prophylactic measures, such as large volume hydration and diuresis during drug administration, a reduction in the glomerular filtration rate (GFR) develops in a small percentage of patients receiving <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>. The incidence and severity of renal failure is correlated with the number of chemotherapy cycles and appears to be partially reversible after treatment is discontinued.</p><p>The most extensive data come from a database study of 1206 males treated with <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) chemotherapy [<a href="#rid19">19</a>]. The GFR was measured prior to treatment, posttreatment, and at one, three, and five years. The decreases in posttreatment GFR for patients receiving 3, 4, or ≥5 cycles of BEP were 11, 15, and 26 percent, respectively. These changes were at least partially reversible. The study also observed a higher than expected incidence of cardiovascular disease and death, but acute changes in GFR did not correlate with the increase in late cardiovascular toxicity. (See <a class="local">'Cardiovascular'</a> below and <a class="local">'Noncancer mortality'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Electrolyte disorders</span><span class="headingEndMark"> — </span>Persistent salt wasting is another manifestation of long-term renal toxicity. In two series, 20 to 30 percent of treated patients had evidence of persisting hypomagnesemia and/or hypophosphatemia an average of four years following chemotherapy [<a href="#rid20">20,21</a>]. One report suggests an even higher proportion of patients with persistent hypomagnesemia, although the clinical significance of this laboratory finding is unknown [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Reducing nephrotoxicity</span><span class="headingEndMark"> — </span>Except for prophylactic measures, such as large volume hydration and diuresis during drug administration, there is no clinically useful method to minimize the risk of nephrotoxicity. Modifications in the treatment regimen that may be associated with a reduced potential for nephrotoxicity include infusional, rather than bolus, <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, substitution of <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> for <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, and the use of protective agents, such as <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a>.</p><p>Despite its more favorable toxicity profile, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a> should not be routinely used in the treatment of testicular GCTs. Although carboplatin is a less nephrotoxic drug than <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, four large randomized trials directly comparing carboplatin with cisplatin in males receiving combination chemotherapy for testicular GCTs have all demonstrated an inferior outcome with carboplatin [<a href="#rid23">23-26</a>]. The use of renal protective agents, such as <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a>, has not been tested in males receiving cisplatin for testicular GCTs.</p><p class="headingAnchor" id="H11"><span class="h2">Drug-induced thrombotic microangiopathy</span><span class="headingEndMark"> — </span>Drug-induced thrombotic microangiopathy (previously called hemolytic uremic syndrome) is a rare complication of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, either alone or with <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> or <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>. (See  <a class="medical medical_review" href="/z/d/html/98720.html" rel="external">"Drug-induced thrombotic microangiopathy (DITMA)"</a>.) </p><p class="headingAnchor" id="H12"><span class="h1">GONADAL EFFECTS</span><span class="headingEndMark"> — </span>Fertility issues are of concern for males with testicular cancer for several reasons. Testicular germ cell tumors (GCTs) are commonly associated with certain conditions resulting in impaired Sertoli cell function and spermatogenesis, such as cryptorchidism or testicular atrophy. Some patients develop testicular cancer as part of a developmental condition known as testicular dysgenesis, which is also characterized by hypospadias, cryptorchidism, and poor semen quality [<a href="#rid27">27</a>]. Furthermore, impaired sperm motility, azoospermia, or severe oligospermia is often present in patients with newly diagnosed testicular cancer prior to therapy [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/2997.html" rel="external">"Epidemiology and risk factors for testicular cancer"</a> and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men", section on 'Testicular cancer'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Spermatogenesis</span><span class="headingEndMark"> — </span>Orchiectomy may lead to further deterioration in spermatogenesis [<a href="#rid29">29,30</a>]. Cisplatin-based chemotherapy is associated with a dose-dependent impairment in fertility, with defects in spermatogenesis [<a href="#rid21">21,31-35</a>] but not sperm motility [<a href="#rid36">36</a>]. The probability of recovery of spermatogenesis is related to treatment intensity (both the number of cycles of chemotherapy and the administered dose), the age of the patient at the time of treatment, and the severity of pretreatment oligospermia [<a href="#rid33">33,37,38</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>At least one report documents no evidence of long-term fertility impairment following two courses of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP) chemotherapy administered in the adjuvant setting for stage I disease [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In contrast, after three to four cycles of chemotherapy, most males develop a transient reduction in spermatogenesis that reaches a minimum 10 to 14 months after treatment [<a href="#rid29">29,33,37,40</a>]. Approximately three years later, sperm production recovers in approximately 70 percent of males [<a href="#rid31">31,33,34,38,41-43</a>]. In the largest series evaluating the time course of recovery of spermatogenesis, yearly sperm counts were assessed in 178 males after standard-dose chemotherapy for testicular GCTs [<a href="#rid33">33</a>]. Of the 89 males with normal pretreatment sperm counts, 64 percent were normal at one year. For all males, the probability of recovering some spermatogenesis was 48 and 80 percent at two and five years, respectively. At the same time points, the likelihood of achieving normal sperm counts was 22 and 58 percent, respectively. It should be noted that some males with persistent oligospermia following chemotherapy can successfully father children [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a> and  <a class="medical medical_review" href="/z/d/html/7452.html" rel="external">"Treatments for male infertility"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher chemotherapy doses (&gt;400 mg/m<sup>2</sup> or &gt;850 mg total dose <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>) are associated with a higher incidence of persistent azoospermia (approximately 50 percent in several studies [<a href="#rid31">31,38,44,45</a>]).</p><p></p><p class="headingAnchor" id="H14"><span class="h2">Hormonal changes</span><span class="headingEndMark"> — </span>Serum testosterone levels are usually normal before chemotherapy in males with testicular cancer, and they are not consistently altered in the short-term by standard chemotherapy doses [<a href="#rid31">31,36,46-48</a>].</p><p>Long-term changes in hormone levels, in contrast, are more prevalent [<a href="#rid36">36,49-52</a>]. In one of the largest series, over 300 testicular cancer survivors originally diagnosed between 1980 and 1994 (median age at diagnosis: 31.5) provided blood samples following orchiectomy at two time points: between 1998 and 2002 (survey I, median age: 42.3) and then between 2007 and 2008 (survey II, median age: 50.4) [<a href="#rid52">52</a>]. Treatment consisted of surgery only, chemotherapy with a platinum-based regimen, or radiation therapy (RT) in approximately 23, 35, and 42 percent of patients, respectively. At survey II, 50 percent of these males had at least one sex hormone level (testosterone, luteinizing hormone [LH], or follicle stimulating hormone [FSH]) outside the normal reference range. Compared with males who were treated with surgery only: </p><p class="bulletIndent1"><span class="glyph">●</span>Males treated with chemotherapy were at significantly higher risk of lower testosterone (odds ratio [OR] 5.2, 95% CI 3.5-7.9), higher FSH (OR 14.2, 95% CI 8.3-24.4), and higher LH levels (OR 3.6, 95% CI 2.4-5.3). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Males treated with RT were also at significantly higher risk of lower testosterone (OR 3.3, 95% CI 2.3-4.7), higher FSH (OR 18.9, 95% CI 11-32.6), and higher LH levels (OR 4.4, 95% CI 3.1-6.5).</p><p></p><p>These data suggest that serial evaluation of hormone levels should be performed as part of the long-term follow-up of testicular cancer survivors. (See  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors", section on 'Hypogonadism'</a>.)</p><p>Other factors that may adversely affect reproductive capability in males with testicular cancer include RT and retroperitoneal lymph node dissection (RPLND). Although older RPLND techniques caused ejaculatory dysfunction in nearly all patients, improvements in surgical technique have reduced the frequency of this complication; furthermore, fewer males undergo RPLND than in the past. (See  <a class="medical medical_review" href="/z/d/html/2992.html" rel="external">"Retroperitoneal lymph node dissection for early-stage testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/z/d/html/2993.html" rel="external">"Treatment of stage I seminoma", section on 'Adjuvant radiation therapy'</a>.)</p><p>Because of these issues, sperm banking is often recommended prior to initiating chemotherapy in young patients who may desire future fertility [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H15"><span class="h1">CARDIOVASCULAR</span><span class="headingEndMark"> — </span>Accumulating evidence suggests that vascular toxicity is one of the most important late consequences of cisplatin-based chemotherapy in the treatment of males with advanced testicular germ cell tumors (GCTs). The major cardiovascular issues that have been studied include dyslipidemia, hypertension, early atherosclerosis and coronary artery disease (CAD), Raynaud phenomenon, and thromboembolic events.</p><p>Long-term survivors of testicular cancer have an increased risk of developing both an unfavorable cardiovascular risk profile and cardiovascular disease following treatment with chemotherapy [<a href="#rid54">54-57</a>]. Although the observed increase in toxicity may be due in part to these risk factors, other mechanisms, including direct vascular toxicity from the chemotherapy, may have a role [<a href="#rid56">56,58,59</a>].</p><p>An increased risk of cardiovascular disease has also been associated with radiation therapy (RT) in patients who receive both subdiaphragmatic and mediastinal RT [<a href="#rid55">55,57</a>]. (See  <a class="medical medical_review" href="/z/d/html/7062.html" rel="external">"Cardiotoxicity of radiation therapy for breast cancer and other malignancies"</a>.)</p><p>In addition to the late consequences of chemotherapy, an increased risk of early cardiovascular events and cardiovascular mortality has been observed [<a href="#rid60">60-62</a>]. However, this association may be due to disease-related factors rather than a causal relationship linked to chemotherapy.</p><p>As an example, in a Surveillance, Epidemiology, and End Results (SEER) database study of 15,006 males treated for nonseminomatous GCT, mortality was significantly increased in those receiving chemotherapy (standardized mortality ratio [SMR] 1.36, 95% CI 1.03-1.78) but not in those treated with surgery alone (SMR 0.81, 95% CI 0.60-1.07). Excess mortality included both heart disease and cerebrovascular disease. The excess mortality was seen predominantly in the first year (SMR 5.31) and subsequently decreased (SMR 1.67 during years 1 to 4, and 1.20 between years 5 and 9).</p><p>The pathophysiologic mechanisms underlying cardiovascular toxicity have not been extensively studied [<a href="#rid60">60,63</a>]. While one study showed increased plasma renin and aldosterone activity following chemotherapy [<a href="#rid63">63</a>], others have found no correlation between hypertension and reduced renal function, or alterations in the renin-angiotensin-aldosterone system. (See  <a class="medical medical_review" href="/z/d/html/3872.html" rel="external">"Overview of hypertension in acute and chronic kidney disease"</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">The metabolic syndrome</span><span class="headingEndMark"> — </span>The metabolic syndrome (hypertension, dyslipidemia, insulin resistance, and obesity) has been reported in many studies of survivors of testicular cancer and may be associated with the cumulative dose of chemotherapy [<a href="#rid64">64-68</a>]. This syndrome has been recognized as a proinflammatory, a prothrombotic state that is associated with elevated levels of C-reactive protein, interleukin (IL)-6, and plasminogen activator inhibitor-1, increasing the risk for subsequent cardiovascular disease and type 2 diabetes. The etiology of the metabolic syndrome in testicular cancer survivors is unclear. (See  <a class="medical medical_review" href="/z/d/html/1784.html" rel="external">"Metabolic syndrome (insulin resistance syndrome or syndrome X)"</a>.)</p><p class="headingAnchor" id="H17"><span class="h2">Hyperlipidemia</span><span class="headingEndMark"> — </span>Males receiving chemotherapy for testicular cancer have alterations in their lipid profiles, possibly due to endocrinologic disturbances [<a href="#rid50">50,69,70</a>]. In one series with a detailed lipid analysis, males previously treated with chemotherapy had a higher mean total cholesterol, a higher ratio of total to high-density lipoprotein (HDL) cholesterol, and more triglycerides compared with those undergoing orchiectomy alone [<a href="#rid71">71</a>]. The previously described study with 10-year follow-up after chemotherapy documented a mean increase in total cholesterol from 181 mg/dL pretreatment to 233 mg/dL posttreatment [<a href="#rid72">72</a>]. (See  <a class="medical medical_review" href="/z/d/html/4553.html" rel="external">"Screening for lipid disorders in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>Chemotherapy can increase blood pressure and cause hypertension [<a href="#rid50">50,57,70-74</a>]. This was illustrated by a series that compared 500 long-term survivors treated with cisplatin-containing chemotherapy with those treated with surgery alone (n = 242), RT (n = 547), or a control group of healthy males (n = 2847); those treated with chemotherapy had a higher prevalence of hypertension than surgically treated patients or controls [<a href="#rid74">74</a>]. The incidence of hypertension was higher in those patients who had received the highest cumulative doses of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (&gt;850 mg).</p><p class="headingAnchor" id="H19"><span class="h2">Myocardial ischemia</span><span class="headingEndMark"> — </span>Several large series have shown that there is an increased risk of ischemic events in long-term survivors of testicular GCTs [<a href="#rid54">54,56,57,74,75</a>]. In one report, the incidence of ischemic heart disease in 2512 long-term survivors in the Netherlands was compared with that of the general population [<a href="#rid54">54</a>]. The standardized incidence ratio for angina or myocardial infarction was 1.17 (95% CI, 1.04-1.31). Factors associated with an increased risk of myocardial infarction included mediastinal irradiation and the use of a cisplatin-containing chemotherapy regimen.</p><p class="headingAnchor" id="H20"><span class="h2">Raynaud phenomenon</span><span class="headingEndMark"> — </span>The Raynaud phenomenon resulting from chemotherapy for GCTs was first described in 1977 [<a href="#rid76">76</a>]. Both <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> have been implicated as causes of secondary Raynaud phenomenon. The incidence is approximately 20 to 40 percent, depending on drug dose and regimen, methods of drug administration, electrolyte levels, and individual risk factors [<a href="#rid72">72,77,78</a>]. Although some series have suggested a correlation between hypomagnesemia and Raynaud phenomenon [<a href="#rid79">79</a>], others have failed to confirm this association [<a href="#rid72">72,73</a>]. In one report, hypertension, but not tobacco use, increased the risk of developing Raynaud phenomenon in association with chemotherapy for testicular cancer [<a href="#rid72">72</a>]. </p><p>Symptoms may begin at any time during treatment and up to three years after the completion of chemotherapy. The particular chemotherapy regimen is of some importance. As an example, in one cohort of 60 males with testicular GCTs receiving chemotherapy, 37 percent developed Raynaud phenomenon within one year, and the incidence was higher with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>, and <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a> (PVB) compared with vinblastine and bleomycin (VB) without cisplatin (41 versus 21 percent) [<a href="#rid79">79</a>]. In a second series of 90 patients, the incidence of Raynaud phenomenon was significantly higher in males receiving PVB compared with cisplatin, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and bleomycin (PEB; 57 versus 25 percent) [<a href="#rid72">72</a>]. Furthermore, continuous infusion bleomycin was associated with a lower incidence than bolus infusion bleomycin [<a href="#rid72">72</a>]. There may be a role for calcium channel blockers in treatment of chemotherapy-induced Raynaud phenomenon [<a href="#rid80">80</a>]. The treatment of Raynaud phenomenon is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7552.html" rel="external">"Treatment of Raynaud phenomenon: Refractory or progressive ischemia"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Thromboembolic events</span><span class="headingEndMark"> — </span>The incidence of thromboembolic events, mainly deep vein thrombosis and pulmonary embolism, is increased in males who are undergoing cisplatin-based therapy for GCTs [<a href="#rid81">81,82</a>]. At least one report suggests that a high body surface area (&gt;1.9 m<sup>2</sup>) and elevated serum levels of lactate dehydrogenase (LDH) predispose patients to thromboembolic events [<a href="#rid82">82</a>]. The risk of a thromboembolic event during therapy was 4 and 26 percent for males with no risk factors and those with at least one risk factor, respectively.</p><p>Rare arterial vascular events following treatment have been reported as well. However, the small number of cases and the limited duration of follow-up have prevented confirmation of this association [<a href="#rid71">71,83</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Changes in body metabolism</span><span class="headingEndMark"> — </span>It has been hypothesized that long-term cardiovascular side effects may be a result of metabolic changes rather than of the chemotherapy itself. Some data show that survivors of chemotherapy-treated testicular cancer have a disproportionate annual increase in body mass index (BMI) [<a href="#rid65">65,70,74</a>]. However, others suggest that this is related to hormonal and age-related changes rather than to chemotherapy [<a href="#rid84">84</a>]. In at least one report of long-term survivors, males undergoing orchiectomy alone for testicular cancer had similar increases in BMI to those who also received chemotherapy [<a href="#rid56">56</a>].</p><p>Patients cured of testicular cancer also have a greater than average level of physical activity, likely as a psychological consequence of their experience with cancer [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H23"><span class="h2">Summary</span><span class="headingEndMark"> — </span>Males who have been treated for testicular GCTs require long-term follow-up that includes a focus on the potential for cardiovascular complications and interventions to reduce the risk of myocardial ischemia. Current guidelines recommend screening for hypertension every two years in individuals over the age of 20 and checking a lipid profile every five years. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors"</a> and  <a class="medical medical_review" href="/z/d/html/1506.html" rel="external">"Overview of established risk factors for cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H24"><span class="h1">NEUROLOGIC</span><span class="headingEndMark"> — </span>Neurologic toxicity is common during treatment. The main culprit is <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, which causes both a distal, mainly sensory, neuropathy with motor sparing and ototoxicity.</p><p class="headingAnchor" id="H25"><span class="h2">Neuropathy</span></p><p class="headingAnchor" id="H580726748"><span class="h3">Cisplatin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> causes an axonal neuropathy that affects predominantly large myelinated sensory fibers. The primary site of damage is the dorsal root ganglion, but the peripheral nerve is also affected. This topic is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy", section on 'Cisplatin'</a>.)</p><p>Most males experience some degree of neuropathy during chemotherapy for testicular cancer [<a href="#rid86">86,87</a>], and further deterioration in the three months following chemotherapy may occur [<a href="#rid88">88</a>]. Patients typically complain of paresthesias, dysesthesias, and disturbances in vibratory and position sense that begin in the toes and fingers, and spread proximally. Patients with mild neuropathy can continue to receive full doses of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>; however, once the neuropathy becomes more severe and begins to interfere with neurologic function, the clinician must weigh the risk of potentially disabling neurotoxicity against the benefit of continued treatment.</p><p>The neuropathy eventually improves in most patients, although recovery is often incomplete [<a href="#rid77">77</a>]. Persistent symptomatic sensory neuropathy is reported in approximately 20 to 30 percent of cases [<a href="#rid77">77,78</a>]. Prophylactic strategies, such as pretreatment with <a class="drug drug_general" data-topicid="8533" href="/z/d/drug information/8533.html" rel="external">amifostine</a>, have been partially successful in delaying or preventing the development of cisplatin-induced neuropathy, but use of this agent is not routine in the treatment of testis cancer. (See  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy", section on 'Cisplatin'</a>.)</p><p class="headingAnchor" id="H3581927147"><span class="h3">Paclitaxel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">Paclitaxel</a>, as part of the TIP regimen for relapsed or refractory testicular germ cell tumors  (<a class="graphic graphic_table graphicRef134377" href="/z/d/graphic/134377.html" rel="external">table 2</a>), is an antimicrotubule agent that can cause peripheral neuropathy. The most common neuropathy caused by paclitaxel involves sensory nerve fibers [<a href="#rid89">89</a>]. (See  <a class="medical medical_review" href="/z/d/html/2999.html" rel="external">"Diagnosis and treatment of relapsed and refractory testicular germ cell tumors", section on 'Treatment after three or four cycles of cisplatin-based chemotherapy'</a>.)</p><p>For patients without pre-existing neuropathy who are treated with TIP, the concurrent administration of <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> is a risk factor for developing paclitaxel-induced sensory neuropathy. Pre-existing neuropathy is also a risk factor for sensory neuropathy with <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, as some patients who are treated with TIP may already have sensory neuropathy from prior exposure to cisplatin during initial therapy. Further details on the risk factors for sensory neuropathy with paclitaxel are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Paclitaxel'</a>.)</p><p class="headingAnchor" id="H709239001"><span class="h3">Vinblastine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">Vinblastine</a> is also a neurotoxin. Replacement of vinblastine with <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> has reduced the incidence of treatment-related neuropathy [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Other vinca alkaloids'</a>.)</p><p class="headingAnchor" id="H26"><span class="h2">Ototoxicity</span><span class="headingEndMark"> — </span>Another common cisplatin-related neurologic effect is ototoxicity, manifested by high-frequency sensorineural hearing loss and tinnitus. (See  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy", section on 'Ototoxicity'</a>.)</p><p>Although some degree of hearing loss is reported by approximately one-half of patients undergoing chemotherapy for testicular cancer, audiometric hearing loss can be detected in almost 90 percent and is often accompanied by tinnitus [<a href="#rid3">3</a>]. Although hearing loss may partially resolve over time, audiometric testing has found that approximately 80 percent of survivors will still have significant hearing loss after four years based on audiometric criteria. The risk of cisplatin-induced ototoxicity is both dose- and schedule-dependent [<a href="#rid3">3,90,91</a>]. Other risk factors include the concurrent administration of other ototoxins and exposure to loud noise (including loud music) [<a href="#rid90">90,92</a>].</p><p class="headingAnchor" id="H38633634"><span class="h2">Cognitive functioning</span><span class="headingEndMark"> — </span>Impaired cognitive function and structural changes on imaging have been observed in patients treated with cisplatin-based chemotherapy [<a href="#rid93">93-96</a>]. (See  <a class="medical medical_review" href="/z/d/html/16347.html" rel="external">"Cognitive function after cancer and cancer treatment"</a>.)</p><p class="headingAnchor" id="H27"><span class="h1">SECOND MALIGNANCIES</span><span class="headingEndMark"> — </span>Second primary cancers have emerged as a leading cause of death among testicular cancer survivors.</p><p class="headingAnchor" id="H28"><span class="h2">Solid tumors</span><span class="headingEndMark"> — </span>The risk of developing or dying from a second malignancy is two to three times greater in survivors of testicular cancer than in the general population [<a href="#rid55">55,75,97-100</a>].</p><p>The largest study to date included 40,576 testicular cancer survivors from 14 population-based tumor registries in Europe and North America; more than 7800 were followed for 20 years, and 2065 were followed for 30 years [<a href="#rid97">97</a>]. Among the most important findings were:</p><p class="bulletIndent1"><span class="glyph">●</span>Among 10-year survivors diagnosed with testicular cancer at an average age of 35 years, the relative risk (RR) of developing a solid tumor relative to expected rates in males from the same registration area of similar age was 1.9 (95% CI 1.8-2.1). Risk remained significantly elevated for at least 35 years. The cumulative risk of developing a solid cancer by age 75 (ie, 40 years after treatment) for males with seminoma and nonseminoma histology was 36 and 31 percent, respectively, compared with 23 percent for the general population.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cancer of the lung (RR 1.5, 95% CI 1.2-1.7), colon (RR 2.0, 95% CI 1.7-2.5), bladder (RR 2.7, 95% CI 2.2-3.1), pancreas (RR 3.6, 95% CI 2.8-4.6), and stomach (RR 4.0, 95% CI 3.2-4.8) accounted for almost 60 percent of the total excess number of solid tumors. In contrast to other studies, this study found that risks were also elevated for mesothelioma (RR 3.4, 95% CI 1.7-5.9) and esophageal cancer (RR 1.7, 95% CI 1.0-2.6). Among males receiving radiation therapy (RT) alone, sites in typical infradiaphragmatic RT fields (ie, bladder, stomach, pancreas, kidney) accounted for 64 percent of the excess cancers.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The RR and excess absolute risk of a second cancer decreased with increasing age at diagnosis of testicular cancer. As an example, a male diagnosed with seminoma at age 20 would have a 47 percent predicted cumulative risk of a solid cancer by age 75; the corresponding rates for a male diagnosed at age 35 or 50 would be 36 and 28 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall patterns were similar for seminoma and nonseminoma, although lower risks were observed for nonseminoma patients treated after 1975.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An increased risk of second solid cancers was seen among males treated with RT alone (RR 2.0, 95% CI 1.9-2.2), chemotherapy alone (RR 1.8, 95% CI 1.3-2.5), and with both modalities (RR 2.9, 95% CI 1.9-4.2).</p><p></p><p class="headingAnchor" id="H29"><span class="h2">Leukemia</span><span class="headingEndMark"> — </span>Males with testicular germ-cell tumors (GCTs) who undergo chemotherapy are also at an increased risk of developing leukemia. (See  <a class="medical medical_review" href="/z/d/html/4506.html" rel="external">"Therapy-related myeloid neoplasms: Epidemiology, causes, evaluation, and diagnosis"</a>.)</p><p>The contribution of RT to risk has not been well characterized. Contemporary studies evaluating large numbers of treated males suggest that the incidence of secondary leukemia is low, &lt;0.5 percent, following a typical three- or four-cycle course of <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">bleomycin</a>, <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>, and <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> (BEP), in which the cumulative etoposide dose is &lt;2000 mg/m<sup>2</sup> [<a href="#rid97">97,101</a>].</p><p>In contrast, prolonged use of high doses of <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a> is associated with a significantly higher risk of secondary myelogenous leukemias that are highly refractory to treatment. Epipodophyllotoxin-induced leukemia is characterized by an onset two to three years following treatment and a hallmark chromosomal translocation involving the long arm of chromosome 11 (11q23) [<a href="#rid102">102</a>]. The risk of secondary leukemia may be as high as 5 percent in those receiving more than 2000 mg/m<sup>2</sup>, representing a 336-fold increase in the likelihood of leukemia [<a href="#rid101">101,103-109</a>]. (See  <a class="medical medical_review" href="/z/d/html/4544.html" rel="external">"Acute myeloid leukemia: Cytogenetic abnormalities"</a>.)</p><p>Combination chemotherapy cures a substantial number of males with advanced testicular GCTs, including 90 percent of those with good-risk advanced disease (see  <a class="medical medical_review" href="/z/d/html/2981.html" rel="external">"Initial risk-stratified treatment for advanced testicular germ cell tumors"</a>). Risk-benefit analyses have concluded that the benefit of standard-dose chemotherapy regimens in advanced GCTs outweighs the risk of treatment-related leukemia. In one review of 18,000 testis cancer survivors, it was estimated that, following standard-dose chemotherapy, 16 cases of secondary leukemia would be expected in 10,000 treated males.</p><p class="headingAnchor" id="H30"><span class="h2">Treatment outcome</span><span class="headingEndMark"> — </span>Concerns exist that second malignancies in testicular cancer survivors might have a worse prognosis due to either late treatment effects preventing effective therapy or altered biology caused by the original treatment [<a href="#rid110">110</a>]. Despite these issues, testicular cancer survivors who develop a second primary malignancy appear to have a similar outcome to comparable patients with a first primary malignancy.</p><p>In a study of 29,356 males with testicular cancer from the Surveillance, Epidemiology, and End Results (SEER) database, 621 cases were identified with a second cancer of known stage [<a href="#rid110">110</a>]. These were compared with 12,420 males with a first primary malignancy; patients were matched for primary site, stage at diagnosis, year of diagnosis, and age. There was no significant increase in either cancer-related mortality (hazard ratio [HR] 1.05, 95% CI 0.90-1.23) or all-cause mortality (HR 1.09, 95% CI 0.96-1.23) compared with the control population.</p><p>The one exception was testicular cancer patients treated between 1973 and 1979, a period when substantially higher doses of RT were used, and RT often included treatment to the thorax. In that subset, there was a significant increase in both cancer-related mortality (HR 1.44, 95% CI 1.13-1.83) and overall mortality (HR 1.65, 95% CI 1.12-2.42).</p><p class="headingAnchor" id="H85966487"><span class="h2">Mitigating risk due to surveillance imaging</span><span class="headingEndMark"> — </span>Guidelines for posttreatment surveillance of males with GCTs include numerous computed tomography (CT) scans over many years. As in other situations requiring repeated exposure to radiation, concern has been raised that the surveillance CT scans may themselves carry a risk of promoting malignancy [<a href="#rid111">111,112</a>]. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The theoretical added lifetime risk may range from 1 to 2 percent for survivors of GCTs, though this number is modeled not on clinical studies in testicular cancer but on data extrapolated from Hiroshima and other radiation exposure situations [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a targeted study of males with GCTs, no added risk of second malignancies was identified in over 2500 males, though with only limited follow-up [<a href="#rid114">114</a>].</p><p></p><p>Clinicians should take into account the age of patients undergoing surveillance when planning the frequency of imaging (particularly by CT), given concerns about second malignancies induced by radiation exposure. Attempts to lower the radiation exposure associated with CT scans with lower radiation dose CT scans or alternative use of magnetic resonance imaging (MRI) may be appropriate to diminish this risk. However, long-term data about the efficacy of these alternate approaches are not available. (See  <a class="medical medical_review" href="/z/d/html/2956.html" rel="external">"Posttreatment follow-up for testicular germ cell tumors", section on 'Radiographic studies'</a> and  <a class="medical medical_review" href="/z/d/html/14236.html" rel="external">"Approach to the care of long-term testicular cancer survivors", section on 'Follow-up for long-term survivors of testicular cancer'</a>.)</p><p class="headingAnchor" id="H31"><span class="h1">NONCANCER MORTALITY</span><span class="headingEndMark"> — </span>Chemotherapy-related toxicity is associated with a small, but statistically significant, increase in late noncancer mortality [<a href="#rid19">19,115</a>]. This was illustrated by a multicenter tumor registry study involving almost 39,000 testicular cancer patients in which noncancer deaths exceeded that expected in the general population by 6 percent (standardized mortality ratio [SMR] 1.06, 95% CI 1.02-1.10) [<a href="#rid115">115</a>]. Although the magnitude of this risk is small, attention to cardiovascular risk factors is important. (See <a class="local">'Cardiovascular'</a> above.)</p><p class="headingAnchor" id="H1416663384"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122274.html" rel="external">"Society guideline links: Testicular cancer"</a>.)</p><p class="headingAnchor" id="H32"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Late treatment-related toxicities in testicular GCTs</strong> – Testicular germ cell tumors (GCTs) are remarkably sensitive to multiple chemotherapy regimens and are curable in approximately 95 percent of patients. Since most males with testicular GCTs are long-term survivors, minimizing the late effects of treatment is a primary concern. Late treatment-related toxicities can affect multiple organ systems, such as:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pulmonary</strong> – <a class="drug drug_general" data-topicid="9160" href="/z/d/drug information/9160.html" rel="external">Bleomycin</a> can cause pneumonitis and pulmonary fibrosis. (See <a class="local">'Pulmonary'</a> above and  <a class="medical medical_review" href="/z/d/html/4316.html" rel="external">"Bleomycin-induced lung injury"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Renal</strong> – <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">Cisplatin</a> is an integral component of the most effective chemotherapy regimens. Cisplatin is nephrotoxic and can be associated with a decrease in the glomerular filtration rate. (See <a class="local">'Renal'</a> above and  <a class="medical medical_review" href="/z/d/html/7231.html" rel="external">"Cisplatin nephrotoxicity"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fertility</strong> – Testicular GCTs are often associated with impaired spermatogenesis. Treatment (orchiectomy, chemotherapy, radiation therapy) can further impair spermatogenesis. (See <a class="local">'Gonadal effects'</a> above and  <a class="medical medical_review" href="/z/d/html/7455.html" rel="external">"Effects of cytotoxic agents on gonadal function in adult men"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiovascular</strong> – Vascular toxicity is one of the most important late consequences of cisplatin-based chemotherapy regimens. Major cardiovascular issues include dyslipidemia, hypertension, early atherosclerosis and coronary artery disease, Raynaud phenomenon, and thromboembolic events. (See <a class="local">'Cardiovascular'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurotoxicity</strong> – Neurologic toxicity is common during treatment. This is primarily associated with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, which typically causes sensory neuropathy with motor sparing and ototoxicity, <a class="drug drug_general" data-topicid="9735" href="/z/d/drug information/9735.html" rel="external">paclitaxel</a>, and <a class="drug drug_general" data-topicid="10044" href="/z/d/drug information/10044.html" rel="external">vinblastine</a>. (See <a class="local">'Neurologic'</a> above and  <a class="medical medical_review" href="/z/d/html/2826.html" rel="external">"Overview of neurologic complications of platinum-based chemotherapy"</a> and  <a class="medical medical_review" href="/z/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Vinca alkaloids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Second malignancies</strong> – Both chemotherapy and radiation therapy have been associated with late secondary malignancies, which are more common in testicular GCT survivors than in the general population. (See <a class="local">'Second malignancies'</a> above.)</p><p></p><p class="headingAnchor" id="H3048632746"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William K Oh, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Williams SD, Birch R, Einhorn LH, et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987; 316:1435.</a></li><li><a class="nounderline abstract_t">Fung C, Sesso HD, Williams AM, et al. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy. J Clin Oncol 2017; 35:1211.</a></li><li><a class="nounderline abstract_t">Frisina RD, Wheeler HE, Fossa SD, et al. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer. J Clin Oncol 2016; 34:2712.</a></li><li><a class="nounderline abstract_t">Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990; 11:1.</a></li><li><a class="nounderline abstract_t">de Wit R, Stoter G, Kaye SB, et al. Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. J Clin Oncol 1997; 15:1837.</a></li><li><a class="nounderline abstract_t">Loehrer PJ Sr, Johnson D, Elson P, et al. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1995; 13:470.</a></li><li><a class="nounderline abstract_t">Levi JA, Raghavan D, Harvey V, et al. The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group. J Clin Oncol 1993; 11:1300.</a></li><li><a class="nounderline abstract_t">de Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001; 19:1629.</a></li><li><a class="nounderline abstract_t">Lehne G, Johansen B, Fosså SD. Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin. Br J Cancer 1993; 68:555.</a></li><li><a class="nounderline abstract_t">McKeage MJ, Evans BD, Atkinson C, et al. Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group. J Clin Oncol 1990; 8:779.</a></li><li><a class="nounderline abstract_t">Comis RL. Detecting bleomycin pulmonary toxicity: a continued conundrum. J Clin Oncol 1990; 8:765.</a></li><li><a class="nounderline abstract_t">Hirsch A, Vander Els N, Straus DJ, et al. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 1996; 14:1297.</a></li><li><a class="nounderline abstract_t">Jensen JL, Goel R, Venner PM. The effect of corticosteroid administration on bleomycin lung toxicity. Cancer 1990; 65:1291.</a></li><li><a class="nounderline abstract_t">Lauritsen J, Kier MG, Bandak M, et al. Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin. J Clin Oncol 2016; 34:1492.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Aass N, Fosså SD, et al. Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol 2009; 27:2779.</a></li><li><a class="nounderline abstract_t">Goldiner PL, Carlon GC, Cvitkovic E, et al. Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J 1978; 1:1664.</a></li><li><a class="nounderline abstract_t">Nygaard K, Smith-Erichsen N, Hatlevoll R, Refsum SB. Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer. Cancer 1978; 41:17.</a></li><li><a class="nounderline abstract_t">Donat SM, Levy DA. Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary? J Urol 1998; 160:1347.</a></li><li><a class="nounderline abstract_t">Lauritsen J, Mortensen MS, Kier MG, et al. Renal impairment and late toxicity in germ-cell cancer survivors. Ann Oncol 2015; 26:173.</a></li><li><a class="nounderline abstract_t">Boyer M, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 1990; 8:21.</a></li><li><a class="nounderline abstract_t">Bokemeyer C, Berger CC, Kuczyk MA, Schmoll HJ. Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 1996; 14:2923.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer 1985; 56:2765.</a></li><li><a class="nounderline abstract_t">Tjulandin SA, Garin AM, Mescheryakov AA, et al. Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors. Ann Oncol 1993; 4:663.</a></li><li><a class="nounderline abstract_t">Bajorin DF, Sarosdy MF, Pfister DG, et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol 1993; 11:598.</a></li><li><a class="nounderline abstract_t">Bokemeyer C, Köhrmann O, Tischler J, et al. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol 1996; 7:1015.</a></li><li><a class="nounderline abstract_t">Horwich A, Sleijfer DT, Fosså SD, et al. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997; 15:1844.</a></li><li><a class="nounderline abstract_t">Jørgensen A, Lindhardt Johansen M, Juul A, et al. Pathogenesis of germ cell neoplasia in testicular dysgenesis and disorders of sex development. Semin Cell Dev Biol 2015; 45:124.</a></li><li><a class="nounderline abstract_t">Fosså SD, Abyholm T, Aakvaag A. Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment. Eur Urol 1984; 10:173.</a></li><li><a class="nounderline abstract_t">Petersen PM, Skakkebaek NE, Rørth M, Giwercman A. Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 1999; 161:822.</a></li><li><a class="nounderline abstract_t">Sibert L, Rives N, Rey D, et al. Semen cryopreservation after orchidectomy in men with testicular cancer. BJU Int 1999; 84:1038.</a></li><li><a class="nounderline abstract_t">Petersen PM, Hansen SW, Giwercman A, et al. Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994; 5:355.</a></li><li><a class="nounderline abstract_t">Stephenson WT, Poirier SM, Rubin L, Einhorn LH. Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 1995; 13:2278.</a></li><li><a class="nounderline abstract_t">Lampe H, Horwich A, Norman A, et al. Fertility after chemotherapy for testicular germ cell cancers. J Clin Oncol 1997; 15:239.</a></li><li><a class="nounderline abstract_t">Nijman JM, Schraffordt Koops H, Kremer J, et al. Fertility and hormonal function in patients with a nonseminomatous tumor of the testis. Arch Androl 1985; 14:239.</a></li><li><a class="nounderline abstract_t">Malone ER, Lewin J, Li X, et al. Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer. Cancer Med 2022; 11:728.</a></li><li><a class="nounderline abstract_t">Hansen SW, Berthelsen JG, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance. J Clin Oncol 1990; 8:1695.</a></li><li><a class="nounderline abstract_t">Aass N, Fosså SD, Theodorsen L, Norman N. Prediction of long-term gonadal toxicity after standard treatment for testicular cancer. Eur J Cancer 1991; 27:1087.</a></li><li><a class="nounderline abstract_t">Brydøy M, Fosså SD, Klepp O, et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97:1580.</a></li><li><a class="nounderline abstract_t">Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14:1106.</a></li><li><a class="nounderline abstract_t">Fosså SD, Theodorsen L, Norman N, Aabyholm T. Recovery of impaired pretreatment spermatogenesis in testicular cancer. Fertil Steril 1990; 54:493.</a></li><li><a class="nounderline abstract_t">Hansen PV, Hansen SW. Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy. Eur Urol 1993; 23:153.</a></li><li><a class="nounderline abstract_t">Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996; 14:441.</a></li><li><a class="nounderline abstract_t">Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004; 100:732.</a></li><li><a class="nounderline abstract_t">Ishikawa T, Kamidono S, Fujisawa M. Fertility after high-dose chemotherapy for testicular cancer. Urology 2004; 63:137.</a></li><li><a class="nounderline abstract_t">Gerl A, Mühlbayer D, Hansmann G, et al. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer 2001; 91:1297.</a></li><li><a class="nounderline abstract_t">Leitner SP, Bosl GJ, Bajorunas D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 1986; 4:1500.</a></li><li><a class="nounderline abstract_t">Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol 1999; 17:1493.</a></li><li><a class="nounderline abstract_t">Lackner J, Schatzl G, Koller A, et al. Treatment of testicular cancer: influence on pituitary-gonadal axis and sexual function. Urology 2005; 66:402.</a></li><li><a class="nounderline abstract_t">Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer 1996; 73:1108.</a></li><li><a class="nounderline abstract_t">Strumberg D, Brügge S, Korn MW, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13:229.</a></li><li><a class="nounderline abstract_t">Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005; 93:200.</a></li><li><a class="nounderline abstract_t">Sprauten M, Brydøy M, Haugnes HS, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol 2014; 32:571.</a></li><li><a class="nounderline abstract_t">Agarwal A. Semen banking in patients with cancer: 20-year experience. Int J Androl 2000; 23 Suppl 2:16.</a></li><li><a class="nounderline abstract_t">van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24:467.</a></li><li><a class="nounderline abstract_t">van den Belt-Dusebout AW, de Wit R, Gietema JA, et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25:4370.</a></li><li><a class="nounderline abstract_t">Huddart RA, Norman A, Shahidi M, et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21:1513.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Wethal T, Aass N, et al. Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 2010; 28:4649.</a></li><li><a class="nounderline abstract_t">Vaughn DJ, Palmer SC, Carver JR, et al. Cardiovascular risk in long-term survivors of testicular cancer. Cancer 2008; 112:1949.</a></li><li><a class="nounderline abstract_t">Altena R, de Haas EC, Nuver J, et al. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 2009; 100:1861.</a></li><li><a class="nounderline abstract_t">Nuver J, Smit AJ, van der Meer J, et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23:9130.</a></li><li><a class="nounderline abstract_t">Dieckmann KP, Gerl A, Witt J, et al. Myocardial infarction and other major vascular events during chemotherapy for testicular cancer. Ann Oncol 2010; 21:1607.</a></li><li><a class="nounderline abstract_t">Fung C, Fossa SD, Milano MT, et al. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. J Clin Oncol 2015; 33:3105.</a></li><li><a class="nounderline abstract_t">Bosl GJ, Leitner SP, Atlas SA, et al. Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors. J Clin Oncol 1986; 4:1684.</a></li><li><a class="nounderline abstract_t">Nuver J, Smit AJ, Wolffenbuttel BH, et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23:3718.</a></li><li><a class="nounderline abstract_t">Nord C, Fosså SD, Egeland T. Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 2003; 88:36.</a></li><li><a class="nounderline abstract_t">Nuver J, Smit AJ, Sleijfer DT, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 2004; 40:701.</a></li><li><a class="nounderline abstract_t">Gietema JA, Meinardi MT, van der Graaf WT, Sleijfer DT. Syndrome X in testicular-cancer survivors. Lancet 2001; 357:228.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Aass N, Fosså SD, et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18:241.</a></li><li><a class="nounderline abstract_t">Raghavan D, Cox K, Childs A, et al. Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 1992; 10:1386.</a></li><li><a class="nounderline abstract_t">Gietema JA, Sleijfer DT, Willemse PH, et al. Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med 1992; 116:709.</a></li><li><a class="nounderline abstract_t">Meinardi MT, Gietema JA, van der Graaf WT, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18:1725.</a></li><li><a class="nounderline abstract_t">Berger CC, Bokemeyer C, Schneider M, et al. Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer. Eur J Cancer 1995; 31A:2229.</a></li><li><a class="nounderline abstract_t">Hansen SW, Groth S, Daugaard G, et al. Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer. J Clin Oncol 1988; 6:1728.</a></li><li><a class="nounderline abstract_t">Sagstuen H, Aass N, Fosså SD, et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005; 23:4980.</a></li><li><a class="nounderline abstract_t">Fosså SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br J Cancer 2004; 90:607.</a></li><li><a class="nounderline abstract_t">Teutsch C, Lipton A, Harvey HA. Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma. Cancer Treat Rep 1977; 61:925.</a></li><li><a class="nounderline abstract_t">Brydøy M, Oldenburg J, Klepp O, et al. Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst 2009; 101:1682.</a></li><li><a class="nounderline abstract_t">Glendenning JL, Barbachano Y, Norman AR, et al. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116:2322.</a></li><li><a class="nounderline abstract_t">Vogelzang NJ, Bosl GJ, Johnson K, Kennedy BJ. Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 1981; 95:288.</a></li><li><a class="nounderline abstract_t">Hantel A, Rowinsky EK, Donehower RC. Nifedipine and oncologic Raynaud phenomenon. Ann Intern Med 1988; 108:767.</a></li><li><a class="nounderline abstract_t">Weijl NI, Rutten MF, Zwinderman AH, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000; 18:2169.</a></li><li><a class="nounderline abstract_t">Gizzi M, Oberic L, Massard C, et al. Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours. Eur J Cancer 2016; 69:151.</a></li><li><a class="nounderline abstract_t">Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. J Clin Oncol 1986; 4:1405.</a></li><li><a class="nounderline abstract_t">Huddart RA, Norman A. Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy. Br J Cancer 2003; 89:1143.</a></li><li><a class="nounderline abstract_t">Thorsen L, Nystad W, Dahl O, et al. The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 2003; 39:1216.</a></li><li><a class="nounderline abstract_t">Thompson SW, Davis LE, Kornfeld M, et al. Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies. Cancer 1984; 54:1269.</a></li><li><a class="nounderline abstract_t">Hansen SW, Helweg-Larsen S, Trojaborg W. Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J Clin Oncol 1989; 7:1457.</a></li><li><a class="nounderline abstract_t">von Schlippe M, Fowler CJ, Harland SJ. Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br J Cancer 2001; 85:823.</a></li><li><a class="nounderline abstract_t">Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012; 14 Suppl 4:iv45.</a></li><li><a class="nounderline abstract_t">Bokemeyer C, Berger CC, Hartmann JT, et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998; 77:1355.</a></li><li><a class="nounderline abstract_t">Travis LB, Fossa SD, Sesso HD, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014; 106.</a></li><li><a class="nounderline abstract_t">Gratton MA, Kamen BA. Potentiation of cisplatin ototoxicity by noise. J Clin Oncol 1990; 8:2091.</a></li><li><a class="nounderline abstract_t">Amidi A, Hosseini SMH, Leemans A, et al. Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy. J Natl Cancer Inst 2017; 109.</a></li><li><a class="nounderline abstract_t">Amidi A, Agerbæk M, Wu LM, et al. Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment. Brain Imaging Behav 2017; 11:769.</a></li><li><a class="nounderline abstract_t">Wefel JS, Vidrine DJ, Marani SK, et al. A prospective study of cognitive function in men with non-seminomatous germ cell tumors. Psychooncology 2014; 23:626.</a></li><li><a class="nounderline abstract_t">Stouten-Kemperman MM, de Ruiter MB, Caan MW, et al. Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Hum Brain Mapp 2015; 36:4638.</a></li><li><a class="nounderline abstract_t">Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354.</a></li><li><a class="nounderline abstract_t">Robinson D, Møller H, Horwich A. Mortality and incidence of second cancers following treatment for testicular cancer. Br J Cancer 2007; 96:529.</a></li><li><a class="nounderline abstract_t">Richiardi L, Scélo G, Boffetta P, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer 2007; 120:623.</a></li><li><a class="nounderline abstract_t">Groot HJ, Lubberts S, de Wit R, et al. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. J Clin Oncol 2018; 36:2504.</a></li><li><a class="nounderline abstract_t">Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Therapy-related malignancies following treatment of germ cell cancer. Int J Cancer 1999; 83:860.</a></li><li><a class="nounderline abstract_t">Ratain MJ, Rowley JD. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol 1992; 3:107.</a></li><li><a class="nounderline abstract_t">Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993; 11:1703.</a></li><li><a class="nounderline abstract_t">Nichols CR, Breeden ES, Loehrer PJ, et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993; 85:36.</a></li><li><a class="nounderline abstract_t">Pedersen-Bjergaard J, Daugaard G, Hansen SW, et al. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet 1991; 338:359.</a></li><li><a class="nounderline abstract_t">Bajorin DF, Motzer RJ, Rodriguez E, et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993; 85:60.</a></li><li><a class="nounderline abstract_t">Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol 1995; 6:35.</a></li><li><a class="nounderline abstract_t">Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol 1999; 17:569.</a></li><li><a class="nounderline abstract_t">Houck W, Abonour R, Vance G, Einhorn LH. Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide. J Clin Oncol 2004; 22:2155.</a></li><li><a class="nounderline abstract_t">Schairer C, Hisada M, Chen BE, et al. Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers. J Natl Cancer Inst 2007; 99:1248.</a></li><li><a class="nounderline abstract_t">Hall EJ, Brenner DJ. Cancer risks from diagnostic radiology. Br J Radiol 2008; 81:362.</a></li><li><a class="nounderline abstract_t">Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol 2012; 30:3752.</a></li><li><a class="nounderline abstract_t">Tarin TV, Sonn G, Shinghal R. Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography. J Urol 2009; 181:627.</a></li><li><a class="nounderline abstract_t">van Walraven C, Fergusson D, Earle C, et al. Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer. J Clin Oncol 2011; 29:2883.</a></li><li><a class="nounderline abstract_t">Fosså SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 2007; 99:533.</a></li></ol></div><div id="topicVersionRevision">Topic 2955 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2437455" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28240972" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354478" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1691067" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bleomycin-induced pulmonary toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164193" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7531223" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7686216" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The importance of bleomycin in combination chemotherapy for good-prognosis germ cell carcinoma. Australasian Germ Cell Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11250991" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7688978" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Long-term follow-up of pulmonary function in patients cured from testicular cancer with combination chemotherapy including bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1692088" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1692087" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Detecting bleomycin pulmonary toxicity: a continued conundrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648387" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1689606" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The effect of corticosteroid administration on bleomycin lung toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26903578" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Pulmonary Function in Patients With Germ Cell Cancer Treated With Bleomycin, Etoposide, and Cisplatin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19414680" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Pulmonary function in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/77697" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Factors influencing postoperative morbidity and mortality in patients treated with bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/75052" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9751352" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bleomycin associated pulmonary toxicity: is perioperative oxygen restriction necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25361985" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Renal impairment and late toxicity in germ-cell cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1688614" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918489" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of long-term toxicity after chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2413982" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Hypomagnesemia, renal dysfunction, and Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8240996" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386751" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9037359" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164194" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26410164" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pathogenesis of germ cell neoplasia in testicular dysgenesis and disorders of sex development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6426966" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Spermatogenesis and hormonal status after orchiectomy for cancer and before supplementary treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10022693" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571631" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Semen cryopreservation after orchidectomy in men with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8075033" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7545220" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8996148" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fertility after chemotherapy for testicular germ cell cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2415075" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fertility and hormonal function in patients with a nonseminomatous tumor of the testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34918879" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1698935" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine, and bleomycin versus surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1720322" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Prediction of long-term gonadal toxicity after standard treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16264178" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Paternity following treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8648364" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2118861" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Recovery of impaired pretreatment spermatogenesis in testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386643" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Gonadal function in men with testicular germ cell cancer: the influence of cisplatin-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8636755" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14770428" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Fertility after testicular cancer treatments: results of a large multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14751366" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Fertility after high-dose chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11283930" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3020183" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gonadal dysfunction in patients treated for metastatic germ-cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10334536" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16040104" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Treatment of testicular cancer: influence on pituitary-gonadal axis and sexual function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624272" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Endocrinological late effects after chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11885999" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15999104" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fertility, gonadal and sexual function in survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24419125" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10849486" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Semen banking in patients with cancer: 20-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421423" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17906202" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12697875" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cardiovascular disease as a long-term complication of treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855830" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18338810" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cardiovascular risk in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19455138" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16301596" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067918" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Myocardial infarction and other major vascular events during chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26240226" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3021923" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ-cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15738540" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556956" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15010071" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11213121" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Syndrome X in testicular-cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060482" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Components of the metabolic syndrome in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1325540" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Hypercholesterolemia after chemotherapy for testis cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558341" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10764433" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8652248" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Secondary Raynaud's phenomenon and other late vascular complications following chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2460594" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Long-term effects on renal function and blood pressure of treatment with cisplatin, vinblastine, and bleomycin in patients with germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16051950" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Blood pressure and body mass index in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14760372" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Increased mortality rates in young and middle-aged patients with malignant germ cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/70274" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940282" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20225230" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6168223" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3358579" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Nifedipine and oncologic Raynaud phenomenon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10811682" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821318" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3528405" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Vascular toxicity associated with antineoplastic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12966440" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Changes in BMI after treatment of testicular cancer are due to age and hormonal function and not chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12763208" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The level of physical activity in long-term survivors of testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6088023" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2476531" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11556831" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23095830" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579846" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24623533" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2230903" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Potentiation of cisplatin ototoxicity by noise.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617869" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Changes in Brain Structural Networks and Cognitive Functions in Testicular Cancer Patients Receiving Cisplatin-Based Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240852" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Changes in cognitive functions and cerebral grey matter and their associations with inflammatory markers, endocrine markers, and APOE genotypes in testicular cancer patients undergoing treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24339329" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : A prospective study of cognitive function in men with non-seminomatous germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26304182" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16174857" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17262080" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Mortality and incidence of second cancers following treatment for testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17096341" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29989856" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10597212" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Therapy-related malignancies following treatment of germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1318741" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8394879" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Secondary neoplasms following treatment of malignant germ cell tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677934" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1713639" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7677936" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7536027" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Secondary tumours following etoposide containing therapy for germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080601" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15169802" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Secondary leukemias in refractory germ cell tumor patients undergoing autologous stem-cell transplantation using high-dose etoposide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17686826" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Comparative mortality for 621 second cancers in 29356 testicular cancer survivors and 12420 matched first cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440940" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cancer risks from diagnostic radiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008318" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091344" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Estimating the risk of cancer associated with imaging related radiation during surveillance for stage I testicular cancer using computerized tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690479" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Association of diagnostic radiation exposure and second abdominal-pelvic malignancies after testicular cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17405998" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Noncancer causes of death in survivors of testicular cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
